Trials / Completed
CompletedNCT01037478
Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma
A Phase 2 Proof of Concept Study to Evaluate the Efficacy, Safety and Pharmacokinetics of the HDAC Inhibitor 4SC-201 in Patients With Relapsed or Refractory Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- 4SC AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Resminostat (4SC-201) is effective and safe in the treatment of relapsed or refractory Hodgkin's Lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Resminostat (4SC-201) | oral administration |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2012-01-01
- Completion
- 2013-03-01
- First posted
- 2009-12-23
- Last updated
- 2014-01-16
Locations
10 sites across 3 countries: Czechia, Poland, Romania
Source: ClinicalTrials.gov record NCT01037478. Inclusion in this directory is not an endorsement.